Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Mi-Jung Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Gastrointestinal cancer
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi
Cancer Res Treat. 2023;55(4):1250-1260.   Published online May 25, 2023
DOI: https://doi.org/10.4143/crt.2023.333
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by  
  • A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
    Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
    Clinical and Translational Oncology.2024;[Epub]     CrossRef
  • 3,677 View
  • 299 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Special Article
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
Jung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, Yu Jung Kim, Jung Hun Kang, Jin Young Kim, Hyo Jin Lee, Woo Kyun Bae, Mi-Jung Kim, Eui Kyu Chie, Jin Kim, Yeul Hong Kim, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(3):851-860.   Published online June 7, 2019
DOI: https://doi.org/10.4143/crt.2019.137
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A cross-sectional survey was conducted to explore the current awareness and use of complementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM experiences among cancer patients and their family members was conducted in 10 oncology clinics in South Korea after institutional review board approval at each institution.
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were male. Most of the patients were actively receiving anticancer treatment at the time of the survey. A total of 106 patients (37%) had experienced a median of two types (interquartile range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI], 1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were independent factors for using CAM in multivariable analysis. Belief in CAM was significantly associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was the most common reason for deciding to use CAM, and only 25% of patients (72/283) discussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with their CAM experiences, and only a small number of patients had an open discussion about CAM with their physicians. A patient education program for CAM is needed.

Citations

Citations to this article as recorded by  
  • Bridging the gap: attitudes and practices toward complementary and alternative medicine among oncology patients and healthcare professionals in Croatia
    Ljerka Armano, Vanja Vasiljev, Tomislav Rukavina, Denis Juraga, Aleksandar Racz, Vanja Tešić
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • The Relationship Between Cancer Patients’ Supportive Care Needs and Their Attitudes Toward Complementary and Alternative Medicine
    H Çelik, H Aslan
    Nigerian Journal of Clinical Practice.2024; 27(4): 415.     CrossRef
  • Complementary and alternative medicine use and its impact on quality of life among cancer patients in Freetown, Sierra Leone: considerations for a resource-limited setting
    Onome T. Abiri, Matilda Seinya Sheriff, Isaac O. Smalle, Nellie V.T. Bell, Ibrahim Franklyn Kamara, Thaim B. Kamara, Constance Cummings-John, Joshua Coker, Abdulai Jawo Bah, Joseph Sam Kanu, Ronita Luke, Lannes Kamara, John Smith, Mohamed Samai
    Discover Medicine.2024;[Epub]     CrossRef
  • Cancer care beyond the conventional: Challenges of integrative oncology in India
    Parvathy Venate, Vitthal G. Huddar
    Ayush Journal of Integrative Oncology.2024; 1(3 & 4): 35.     CrossRef
  • Alternative and complementary medicine in neurological disorders and neurological disability patients: Prevalence, factors, opinions and reasons
    Paul Carrillo-Mora, Marlene A. Rodríguez-Barragán, Jimena Quinzaños-Fresnedo, María del Refugio Pacheco-Gallegos, María Soto-Lara, Monserrat Velázquez-Ortega, María Fernanda Villarreal-Azamar, Ilse Jocelyn Aguirre-Medina, Mariana Rubalcava-Gracia-Medrano
    Complementary Therapies in Medicine.2023; 72: 102920.     CrossRef
  • Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
    Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
    Cancer Research and Treatment.2023; 55(2): 442.     CrossRef
  • Effects of COVID-19 fear and anxiety on attitudes towards complementary and alternative medicine use in women with gynecological cancer during the COVID-19 pandemic
    Fatma Uslu-Sahan, Ilknur Yesilcınar, Gonul Kurt, Elif Hancer, Gulten Guvenc
    Journal of Integrative Medicine.2023; 21(4): 377.     CrossRef
  • Use of Complementary and Alternative Medicine for Prostate Cancer among African Americans, African Immigrants and Caribbean Immigrants
    Nipher Malika, Lisa Roberts, Carlos Casiano, Susanne Montgomery
    Journal of Community Health.2022; 47(2): 284.     CrossRef
  • Traditional and complementary medicine use among cancer patients in Nepal: a cross-sectional survey
    Soo Jeung Choi, Sangita Karki Kunwor, Hyea Bin Im, Jung Hye Hwang, Dain Choi, Dongwoon Han
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • The effect of cancer on traditional, complementary and alternative medicine utilization in Korea: a fixed effect analysis using Korea Health Panel data
    Dongsu Kim, Soo-Hyun Sung, Seungwon Shin, Minjung Park
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • Use of Complementary and Alternative Medicine (CAM) in Patients With Colorectal Cancer
    Jeongwon Yeom, Jung Mi Lee
    Clinical Nutrition Research.2022; 11(4): 255.     CrossRef
  • Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis
    Kyeore Bae
    The Journal of Internal Korean Medicine.2022; 43(6): 1075.     CrossRef
  • Borders between integrative medicine and EBM: significance, potential for use and legal issues in European Union member states. Narrative review
    Aneta Brygida Jędrzejewska, Barbara Janina Ślusarska, Grzegorz Józef Nowicki
    Pielegniarstwo XXI wieku / Nursing in the 21st Century.2022; 21(2): 122.     CrossRef
  • Evaluation of outpatient cancer patients’ use of nonpharmacological methods in the management of chemotherapy-induced nausea and vomiting
    Eda ERGİN, Tülay SAĞKAL MİDİLLİ, Eda AKDAĞ, Ceyda KIRGÖZ
    Cukurova Medical Journal.2021; 46(2): 574.     CrossRef
  • The Current Status of Integrative Oncology in Korea
    Eun-Bin Kwag, Soo-Dam Kim, Ji Hye Park, So-Jung Park, Mi-Kyung Jeong, Hwa-Seung Yoo
    Integrative Cancer Therapies.2021;[Epub]     CrossRef
  • Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood
    Kathryn Knecht, David Kinder, Amy Stockert
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study
    Eun Hye Kim, Jee-Hyun Yoon, Sung Soo Yoon, Jee Young Lee, Seong Woo Yoon
    Integrative Cancer Therapies.2020;[Epub]     CrossRef
  • 9,381 View
  • 225 Download
  • 15 Web of Science
  • 17 Crossref
Close layer
Original Articles
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
Keun-Wook Lee, Bum Jun Kim, Mi-Jung Kim, Hye Sook Han, Jin Won Kim, Young Iee Park, Sook Ryun Park
Cancer Res Treat. 2017;49(3):706-716.   Published online October 18, 2016
DOI: https://doi.org/10.4143/crt.2016.216
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen.
Materials and Methods
Patients with progressive disease after first-line cisplatin plus S-1 or capecitabine were randomized to receive 3-week cycles of docetaxel 75 mg/m2 intravenously (IV) on D1 (D), docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m² IV on D1 (DC), or docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS).
Results
Seventy-two patients were randomized to the D (n=23), DC (n=24), or DS (n=25) group. The confirmed response rate was 4.3% (95% confidence interval [CI], 0% to 12.6%), 4.3% (95% CI, 0% to 12.6%), and 8.7% (95% CI, 0% to 20.2%) for the D, DC, and DS groups, respectively. Compared to the D arm, the DS arm had a better progression-free survival (2.7 months vs. 1.3 months, p=0.034) without any deterioration in safety or quality of life, whereas the DC arm had a similar progression-free survival (1.8 months vs. 1.3 months, p=0.804) and poorer overall survival (5.6 months vs. 10.0 months, p=0.035).
Conclusion
A re-challenge with S-1, but not cisplatin, in combination with docetaxel has potential anticancer benefits over docetaxel alone in MGC with progression after prior cisplatin plus S-1 or capecitabine.

Citations

Citations to this article as recorded by  
  • Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab
    Yulia D’yachkova, Astra M. Liepa, Rajat Goel, Veronika Earley-Valovic, Abby Paine, Palvi Gupta, Kaisa Taipale
    Journal of Gastrointestinal Cancer.2025;[Epub]     CrossRef
  • Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
    Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis
    Lauren A. Abderhalden, Ping Wu, Mayur M. Amonkar, Brian M. Lang, Sukrut Shah, Fan Jin, Andrew M. Frederickson, Ali Mojebi
    Journal of Gastrointestinal Cancer.2023; 54(4): 1031.     CrossRef
  • Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies
    J. Hack, S.J. Crabb
    Clinical Oncology.2022; 34(8): e329.     CrossRef
  • Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
    Alison Rowsell, Samantha C. Sodergren, Vassilios Vassiliou, Anne-Sophie Darlington, Marianne G. Guren, Bilal Alkhaffaf, Chantelle Moorbey, Kristopher Dennis, Mitsumi Terada
    Gastric Cancer.2022; 25(4): 665.     CrossRef
  • Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology
    Elisabeth Coart, Everardo D. Saad
    Expert Review of Precision Medicine and Drug Development.2021; 6(4): 271.     CrossRef
  • Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
    Daniel V. Catenacci, Joseph Chao, Kei Muro, Salah Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem
    The Oncologist.2021; 26(10): e1704.     CrossRef
  • Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
    Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
    N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
    Medical Council.2019; (10): 100.     CrossRef
  • Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
    Bo Li, Lian Chen, Hong-Liang Luo, Feng-Ming Yi, Yi-Ping Wei, Wen-Xiong Zhang
    World Journal of Clinical Cases.2019; 7(5): 600.     CrossRef
  • A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
    Dan Zhang, Jia-Rui Wu, Xiao-Jiao Duan, Kai-Huan Wang, Yi Zhao, Meng-Wei Ni, Shu-Yu Liu, Xiao-Meng Zhang, Bing Zhang
    Frontiers in Pharmacology.2019;[Epub]     CrossRef
  • Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis
    Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao
    Critical Reviews in Oncology/Hematology.2019; 143: 27.     CrossRef
  • Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis
    Jessy Joy van Kleef, Emil ter Veer, Héctor G van den Boorn, Sandor Schokker, Lok Lam Ngai, Mariska J Prins, Nadia Haj Mohammad, Lonneke V van de Poll-Franse, Aeilko H Zwinderman, Martijn G H van Oijen, Mirjam A G Sprangers, Hanneke W M van Laarhoven
    JNCI: Journal of the National Cancer Institute.2019;[Epub]     CrossRef
  • 10,811 View
  • 358 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
Mi-Jung Kim, Sae-Won Han, Dae-Won Lee, Yongjun Cha, Kyung-Hun Lee, Tae-Yong Kim, Do-Youn Oh, Se Hyung Kim, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
Cancer Res Treat. 2016;48(3):990-997.   Published online January 14, 2016
DOI: https://doi.org/10.4143/crt.2015.296
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Splenomegaly is a clinical surrogate of oxaliplatin-induced sinusoidal obstruction syndrome (SOS). We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients.
Materials and Methods
Splenomegaly was determined by spleen volumetry using computed tomography images obtained before initiation of chemotherapy and after completion of adjuvant FOLFOX in CRC patients. Ten genetic polymorphisms in 4 SOS-related genes (VEGFA, MMP9, NOS3, and GSTP1) were analyzed using DNA from peripheral blood mononuclear cells.
Results
Of 124 patients included, increase in spleen size was observed in 109 (87.9%). Median change was 31% (range, –42% to 168%). Patients with splenomegaly had more severe thrombocytopenia compared to patients without splenomegaly during the chemotherapy period (p < 0.0001). The cumulative dose of oxaliplatin and the lowest platelet count during the chemotherapy period were clinical factors associated with splenomegaly. However, no significant associations were found between genetic polymorphisms and development of splenomegaly. Disease-free survival was similar regardless of the development of splenomegaly.
Conclusion
Splenomegaly was frequently observed in patients receiving adjuvant FOLFOX and resulted in more severe thrombocytopenia but did not influence treatment outcome. Examined genetic polymorphisms did not predict development of splenomegaly.

Citations

Citations to this article as recorded by  
  • Association of VEGF promoter polymorphisms with gastrointestinal tract cancer risk and therapy response: a systematic review
    Deepanshi Mahajan, Vasudha Sambyal, Kamlesh Guleria
    Egyptian Journal of Medical Human Genetics.2025;[Epub]     CrossRef
  • Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy
    Kadriye Bir Yücel, Atiye Cenay Karabörk Kilic, Osman Sütcüoglu, Ozan Yazıcı, Koray Kilic, Gözde Savaş, Aytug Uner, Nazan Günel, Ahmet Özet, Nuriye Özdemir
    Journal of Chemotherapy.2024; 36(3): 249.     CrossRef
  • Effects of methanolic leaf extract and fractions of Irvingia gabonensis on hematological parameters in Wistar rats with splenomegaly
    Fidelia Okoben, InnocentMary Ejiofor, Ikechukwu Mbagwu, Daniel Ajaghaku, Fredrick Anowi
    Sciences of Pharmacy.2024; 3(1): 11.     CrossRef
  • Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
    A. Puente, J.I. Fortea, C. Del Pozo, M. Serrano, M. Alonso-Peña, A. Giráldez, L. Tellez, J. Martinez, M. Magaz, L. Ibañez, J. Garcia, E. Llop, C. Alvarez-Navascues, M. Romero, E. Rodriguez, M.T. Arias Loste, A. Antón, V. Echavarria, C. López, A. Albillos,
    Digestive and Liver Disease.2024; 56(10): 1721.     CrossRef
  • The “appearing” and “disappearing” ascites in the treatment of colorectal cancer: a case report
    Hong-Ming Cui, Xin-Peng Shu, Zheng-Qiang Wei, Xing-Ye Wu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • A contrast-enhanced CT-based whole-spleen radiomics signature for early prediction of oxaliplatin-related thrombocytopenia in patients with gastrointestinal malignancies: a retrospective study
    Yuhong Dai, Yiqi Cheng, Ziling Zhou, Zhen Li, Yan Luo, Hong Qiu
    PeerJ.2023; 11: e16230.     CrossRef
  • Natural Language Processing of Large-Scale Structured Radiology Reports to Identify Oncologic Patients With or Without Splenomegaly Over a 10-Year Period
    Simon Sun, Kaelan Lupton, Karen Batch, Huy Nguyen, Lior Gazit, Natalie Gangai, Jessica Cho, Kevin Nicholas, Farhana Zulkernine, Varadan Sevilimedu, Amber Simpson, Richard K. G. Do
    JCO Clinical Cancer Informatics.2022;[Epub]     CrossRef
  • Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome
    Chen Zhu, Xinwei Cheng, Ping Gao, Qianyan Gao, Ximin Wang, Dong Liu, Xiuhua Ren, Chengliang Zhang
    Molecular Medicine Reports.2022;[Epub]     CrossRef
  • Oxaliplatin-induced hepatic sinusoidal obstruction syndrome
    Chen Zhu, Xiuhua Ren, Dong Liu, Chengliang Zhang
    Toxicology.2021; 460: 152882.     CrossRef
  • Association between single nucleotide polymorphisms (SNPs) of IL1, IL12, IL28 and TLR4 and symptoms of congenital cytomegalovirus infection
    Dominika Jedlińska-Pijanowska, Beata Kasztelewicz, Justyna Czech-Kowalska, Maciej Jaworski, Klaudia Charusta-Sienkiewicz, Anna Dobrzańska, Michael Nevels
    PLOS ONE.2020; 15(5): e0233096.     CrossRef
  • Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan
    Ryo Ohta, Takeshi Yamada, Keisuke Hara, Takuma Iwai, Kohji Tanakaya, Keiichiro Ishibashi, Kazuhiko Yoshimatsu, Chihiro Kosugi, Masahiro Tsubaki, Hideo Nakajima, Masatoshi Oya, Hiroshi Yoshida, Keiji Koda, Hideyuki Ishida
    International Journal of Clinical Oncology.2020; 25(12): 2075.     CrossRef
  • Oxaliplatin-induced haematological toxicity and splenomegaly in mice
    Justin G. Lees, Daniel White, Brooke A. Keating, Mallory E. Barkl-Luke, Preet G. S. Makker, David Goldstein, Gila Moalem-Taylor, Senthilnathan Palaniyandi
    PLOS ONE.2020; 15(9): e0238164.     CrossRef
  • Olive Oil‐Based Ultrafine Theranostic Photo Nanoemulsions: A Versatile Tumor Maneuvering Nanoplatform for Precise Controlled Drug Release in Tumor and Complete Tumor Eradication Mediated by Photo‐Chemotherapy
    N. Sanoj Rejinold, Kondareddy Cherukula, Jong Hoon Ha, In‐Kyu Park, Yeu‐Chun Kim
    Advanced Therapeutics.2019;[Epub]     CrossRef
  • Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer
    Jeonghyun Kang, Joon Seong Park, Sung Gwe Ahn, Jin Hong Lim, Seung Hyuk Baik, Dong Sup Yoon, Kang Young Lee, Joon Jeong
    Annals of Surgical Treatment and Research.2018; 95(3): 161.     CrossRef
  • Automatized spleen segmentation in non-contrast-enhanced MR volume data using subject-specific shape priors
    Oliver Gloger, Klaus Tönnies, Robin Bülow, Henry Völzke
    Physics in Medicine & Biology.2017; 62(14): 5861.     CrossRef
  • UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
    Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou, Yong Tang
    Cancer Chemotherapy and Pharmacology.2016; 78(1): 119.     CrossRef
  • 12,979 View
  • 158 Download
  • 19 Web of Science
  • 16 Crossref
Close layer
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Do-Youn Oh, Se-Hoon Lee, Sae-Won Han, Mi-Jung Kim, Tae-Min Kim, Tae-You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung-Jue Bang
Cancer Res Treat. 2015;47(4):607-615.   Published online February 26, 2015
DOI: https://doi.org/10.4143/crt.2014.249
AbstractAbstract PDFPubReaderePub
Purpose
OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received OPB-31121 once daily for 28 days of each cycle followed by 2 weeks rest. A standard 3+3 design was used for dose-escalation. Safety and response were evaluated by the National Cancer Institute–Common Terminology Criteria for Adverse Events (NCICTCAE) ver. 3.0 and Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.0, respectively.
Results
Twenty-five patients were treated with OPB-31121 at five dose levels: 100 mg (n=4), 200 mg (n=3), 400 mg (n=3), 600 mg (n=7), and 800 mg (n=8). Seven patients discontinued treatment during cycle 1 for various reasons other than study drug-related adverse events. Among 18 patients who were evaluable for dose-limiting toxicity (DLT), three DLTs were observed: one DLT (grade 3 vomiting) at 600 mg and two DLTs (grade 3 vomiting, grade 3 diarrhea) at 800 mg. The MTD was determined as 800 mg/day. Common adverse events were gastrointestinal adverse event including nausea (84%), vomiting (80%), and diarrhea (72%). Pharmacokinetics did not demonstrate dose-proportionality of OPB-31121. Eight patients had stable disease and 10 patients had disease progression. Two patients (1 colon cancer, 1 rectal cancer) showed tumor shrinkage. One gastric cancer patient continued treatment up to cycle 13 before disease progression. Conclusion This study demonstrates feasibility of STAT3 inhibition in patients with advanced solid tumor. OPB-31121, at the MTD of 800 mg/day, was safe and relatively well tolerated, and has a preliminary antitumor activity.

Citations

Citations to this article as recorded by  
  • Expression of STAT3, IL27p28 and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria
    Sahar Rastgoo, Mojgan Mohammadi, Marcus Maurer, Mahdi Atabaki, Jalil Tavakkol-Afshari, Maryam Khoshkhui
    Clinical and Experimental Dermatology.2025; 50(2): 357.     CrossRef
  • Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy
    Win Lwin Thuya, Yang Cao, Paul Chi-Lui Ho, Andrea Li-Ann Wong, Lingzhi Wang, Jianbiao Zhou, Christophe Nicot, Boon Cher Goh
    Cytokine & Growth Factor Reviews.2025;[Epub]     CrossRef
  • CTSL Promotes Autophagy in Laryngeal Cancer Through the IL6‐JAK‐STAT3 Signalling Pathway
    Xueying Wang, Junrong Wang, Lei Wang, Ming Song, Hongxue Meng, Erliang Guo, Susheng Miao
    Journal of Cellular and Molecular Medicine.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma: signaling pathways and therapeutic advances
    Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin
    Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
  • Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
    Yamei Hu, Zigang Dong, Kangdong Liu
    Journal of Experimental & Clinical Cancer Research.2024;[Epub]     CrossRef
  • Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
    Greta Pessino, Claudia Scotti, Maristella Maggi
    Cancers.2024; 16(5): 901.     CrossRef
  • Impact of STAT-signaling pathway on cancer-associated fibroblasts in colorectal cancer and its role in immunosuppression
    Damián Sánchez-Ramírez, Mónica G Mendoza-Rodríguez, Omar R Alemán, Fernando A Candanedo-González, Miriam Rodríguez-Sosa, Juan José Montesinos-Montesinos, Mauricio Salcedo, Ismael Brito-Toledo, Felipe Vaca-Paniagua, Luis I Terrazas
    World Journal of Gastrointestinal Oncology.2024; 16(5): 1705.     CrossRef
  • Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
    Julia Martínez-Pérez, Carlos Torrado, María A. Domínguez-Cejudo, Manuel Valladares-Ayerbes
    International Journal of Molecular Sciences.2024; 25(11): 6220.     CrossRef
  • Interleukin-6 serves as a critical factor in various cancer progression and therapy
    Asma’a H. Mohamed, Abdulrahman T. Ahmed, Waleed Al Abdulmonem, Dmitry Olegovich Bokov, Alaa Shafie, Hussein Riyadh Abdul Kareem Al-Hetty, Chou-Yi Hsu, Mohammed Alissa, Shahid Nazir, Mohammad Chand Jamali, Mustafa Mudhafar
    Medical Oncology.2024;[Epub]     CrossRef
  • Targeting cytokine and chemokine signaling pathways for cancer therapy
    Ming Yi, Tianye Li, Mengke Niu, Haoxiang Zhang, Yuze Wu, Kongming Wu, Zhijun Dai
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Recent advances in targeted drug delivery systems for multiple myeloma
    Ashruti Pant, Aayushi Laliwala, Sarah A. Holstein, Aaron M. Mohs
    Journal of Controlled Release.2024; 376: 215.     CrossRef
  • A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: Advances and insights
    Suryaa Manoharan, Ekambaram Perumal
    Fitoterapia.2024; 179: 106265.     CrossRef
  • The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
    Mengxuan Zhu, Suyao Li, Xin Cao, Khalid Rashid, Tianshu Liu
    Seminars in Cancer Biology.2023; 88: 18.     CrossRef
  • Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
    Xiaoqing Guan, Jing Yang, Weiyi Wang, Bing Zhao, Shiyu Hu, Dehua Yu, Li Yuan, Yunfu Shi, Jingli Xu, Jinyun Dong, Jinxin Wang, Xiang-Dong Cheng, Jiang-Jiang Qin
    Pharmacological Research.2023; 189: 106703.     CrossRef
  • JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
    Qian Hu, Qihui Bian, Dingchao Rong, Leiyun Wang, Jianan Song, Hsuan-Shun Huang, Jun Zeng, Jie Mei, Peng-Yuan Wang
    Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
  • Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay
    Xueying Fan, Mingjing Meng, Baoting Li, Hui Chen, Jincheng Tan, Keyang Xu, Shilin Xiao, Hiu-Yee Kwan, Zhongqiu Liu, Tao Su
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Application of Nano-Antibodies for Cancer Immunotherapy
    Sunanda Singh, Samara P. Singh, Ashutosh S. Parihar
    Current Tissue Microenvironment Reports.2023; 4(2): 17.     CrossRef
  • Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
    Yan-Ruide Li, Ying Fang, Zibai Lyu, Yichen Zhu, Lili Yang
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice
    Yuko Ono, Masafumi Saito, Kazuho Sakamoto, Yuko Maejima, Shingen Misaka, Kenju Shimomura, Nobuto Nakanishi, Shigeaki Inoue, Joji Kotani
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer
    Madhuvanthi Giridharan, Vasu Rupani, Satarupa Banerjee
    ACS Pharmacology & Translational Science.2022; 5(4): 193.     CrossRef
  • Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
    Ranzhiqiang Yang, Yinghui Song, Kashif Shakoor, Weimin Yi, Chuang Peng, Sulai Liu
    Molecular Medicine Reports.2022;[Epub]     CrossRef
  • Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
    Shumin Ouyang, Huaxuan Li, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu, Yuanxiang Wang, Xiaolei Zhang
    Redox Biology.2022; 52: 102317.     CrossRef
  • Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
    Yanhong Ni, Jun T. Low, John Silke, Lorraine A. O’Reilly
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
    Sunanda Singh, Genoveva Murillo, Justin Richner, Samara P. Singh, Erica Berleth, Vijay Kumar, Rajendra Mehta, Vijay Ramiya, Ashutosh S. Parihar
    International Journal of Molecular Sciences.2022; 23(14): 7565.     CrossRef
  • Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy
    Elham Patrad, Solmaz Khalighfard, Taghi Amiriani, Vahid Khori, Ali Mohammad Alizadeh
    Cellular Oncology.2022; 45(6): 1073.     CrossRef
  • STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
    Mingjing Jiang, Bo Li
    Cells.2022; 11(19): 3131.     CrossRef
  • The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
    Magdalena Rašková, Lukáš Lacina, Zdeněk Kejík, Anna Venhauerová, Markéta Skaličková, Michal Kolář, Milan Jakubek, Daniel Rosel, Karel Smetana, Jan Brábek
    Cells.2022; 11(22): 3698.     CrossRef
  • An update on investigational therapies that target STAT3 for the treatment of cancer
    Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
    Expert Opinion on Investigational Drugs.2021; 30(3): 245.     CrossRef
  • RETRACTED: GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
    Weiliang Jiang, Congying Chen, Li Huang, Jie Shen, Lijuan Yang
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models
    Sun Young Moon, Kwang Dong Kim, Jiyun Yoo, Jeong-Hyung Lee, Cheol Hwangbo
    Molecules.2021; 26(9): 2824.     CrossRef
  • Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma
    Chuanchuan Zhan, Chao Xu, Jiajun Chen, Chong Shen, Jinkun Li, Zichu Wang, Xiangrong Ying, Zhengang Luo, Yu Ren, Gangfeng Wu, Haojie Zhang, Manfei Qian
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas
    Cyndy Liu, Tae Nakano-Tateno, Motoyasu Satou, Constance Chik, Toru Tateno
    Endocrine Journal.2021; 68(10): 1143.     CrossRef
  • The JAK/STAT signaling pathway: from bench to clinic
    Xiaoyi Hu, Jing li, Maorong Fu, Xia Zhao, Wei Wang
    Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
  • Interleukin-6 and colorectal cancer development
    I.А. Hromakova, P.P. Sorochan, N.E. Prokhach, I.S. Hromakova
    Український радіологічний та онкологічний журнал.2021; 29(4): 89.     CrossRef
  • Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway
    Haixiang Ding, Xiuchong Yu, Zhilong Yan
    International Journal of Molecular Medicine.2021;[Epub]     CrossRef
  • Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells
    Kimberly M. Arnold, Lynn M. Opdenaker, Nicole J. Flynn, Daniel Kwesi Appeah, Jennifer Sims-Mourtada
    International Journal of Radiation Biology.2020; 96(4): 434.     CrossRef
  • Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
    Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
    Journal of the American Chemical Society.2020; 142(6): 2876.     CrossRef
  • Phosphotyrosine isosteres: past, present and future
    Robert A. Cerulli, Joshua A. Kritzer
    Organic & Biomolecular Chemistry.2020; 18(4): 583.     CrossRef
  • Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1
    Hai Zhang, Yu-ping Tan, Lin Zhao, Lun Wang, Nai-jie Fu, Song-ping Zheng, Xiao-fei Shen
    Cell Death & Disease.2020;[Epub]     CrossRef
  • JAK/STAT signaling in hepatocellular carcinoma
    Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
    Hepatic Oncology.2020;[Epub]     CrossRef
  • JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
    Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
    Nature Reviews Gastroenterology & Hepatology.2020; 17(6): 323.     CrossRef
  • Targeting STAT3 in cancer and autoimmune diseases
    Tohid Gharibi, Zohreh Babaloo, Arezoo Hosseini, Meghdad Abdollahpour-alitappeh, Vida Hashemi, Faroogh Marofi, Kazem Nejati, Behzad Baradaran
    European Journal of Pharmacology.2020; 878: 173107.     CrossRef
  • Betacellulin drives therapy resistance in glioblastoma
    Qiwen Fan, Zhenyi An, Robyn A Wong, Xujun Luo, Edbert D Lu, Albert Baldwin, Manasi K Mayekar, Franziska Haderk, Kevan M Shokat, Trever G Bivona, William A Weiss
    Neuro-Oncology.2020; 22(4): 457.     CrossRef
  • A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction
    Soo Kyung Park, Woong Sub Byun, Seungbeom Lee, Young Taek Han, Yoo-Seong Jeong, Kyungkuk Jang, Suk-Jae Chung, Jeeyeon Lee, Young-Ger Suh, Sang Kook Lee
    Biochemical Pharmacology.2020; 178: 114053.     CrossRef
  • STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
    Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
    Biology.2020; 9(6): 126.     CrossRef
  • Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives
    Matteo Mori, Ettore Gilardoni, Luca Regazzoni, Alessandro Pedretti, Diego Colombo, Gary Parkinson, Akira Asai, Fiorella Meneghetti, Stefania Villa, Arianna Gelain
    Molecules.2020; 25(15): 3509.     CrossRef
  • STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
    Ping-Lian Yang, Lu-Xin Liu, En-Min Li, Li-Yan Xu
    Cancers.2020; 12(9): 2459.     CrossRef
  • Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer


    Yan Lin, Ziqin He, Jiazhou Ye, Ziyu Liu, Xiaomin She, Xing Gao, Rong Liang
    OncoTargets and Therapy.2020; Volume 13: 13023.     CrossRef
  • Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
    Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
    Current Gene Therapy.2020; 20(2): 84.     CrossRef
  • Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
    Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
    Cancers.2019; 11(2): 248.     CrossRef
  • Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
    Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
    Cancer Research and Treatment.2019; 51(2): 510.     CrossRef
  • IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2
    Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Lijun Xu, Xiang Xue, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen
    Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1471.     CrossRef
  • Proton pump inhibitor: The dual role in gastric cancer
    Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
    World Journal of Gastroenterology.2019; 25(17): 2058.     CrossRef
  • Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
    Gianluca Civenni, Domenico Albino, Dheeraj Shinde, Ramiro Vázquez, Jessica Merulla, Aleksandra Kokanovic, Sarah N. Mapelli, Giuseppina M. Carbone, Carlo V. Catapano
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
    Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
    Emily A. Irey, Chelsea M. Lassiter, Nicholas J. Brady, Pavlina Chuntova, Ying Wang, Todd P. Knutson, Christine Henzler, Thomas S. Chaffee, Rachel I. Vogel, Andrew C. Nelson, Michael A. Farrar, Kathryn L. Schwertfeger
    Proceedings of the National Academy of Sciences.2019; 116(25): 12442.     CrossRef
  • Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival
    Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy
    Journal of Advanced Research.2019; 20: 105.     CrossRef
  • Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells
    Liang Zhang, Timothy E. Peterson, Victor M. Lu, Ian F. Parney, David J. Daniels, Ilya Ulasov
    PLOS ONE.2019; 14(7): e0220569.     CrossRef
  • Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis
    Yali Li, Cailing Gan, Yange Zhang, Yan Yu, Chen Fan, Yuanle Deng, Qianyu Zhang, Xi Yu, Yiwen Zhang, Liqun Wang, Fang He, Yongmei Xie, Tinghong Ye, Wenya Yin
    Frontiers in Pharmacology.2019;[Epub]     CrossRef
  • Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status
    Tadashi Ashizawa, Akira Iizuka, Chie Maeda, Emiko Tanaka, Ryota Kondou, Haruo Miyata, Takashi Sugino, Takuya Kawata, Shoichi Deguchi, Koichi Mitsuya, Nakamasa Hayashi, Akira Asai, Mamoru Ito, Ken Yamaguchi, Yasuto Akiyama
    Immunology Letters.2019; 216: 43.     CrossRef
  • Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
    Arianna Gelain, Matteo Mori, Fiorella Meneghetti, Stefania Villa
    Current Medicinal Chemistry.2019; 26(27): 5165.     CrossRef
  • The effects of signal transducer and activator of transcription three mutations on human platelets
    Floor E. Aleva, Frank L. van de Veerdonk, Yang Li, Rahajeng N. Tunjungputri, Sami Simons, Philip G. De Groot, Mihai M. Netea, Yvonne F. Heijdra, Quirijn de Mast, André J.A.M. van der Ven
    Platelets.2018; 29(6): 602.     CrossRef
  • Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models
    Won Gu Kim, Sheue-yann Cheng
    Hormones and Cancer.2018; 9(2): 108.     CrossRef
  • Targeting the IL-6/JAK/STAT3 signalling axis in cancer
    Daniel E. Johnson, Rachel A. O'Keefe, Jennifer R. Grandis
    Nature Reviews Clinical Oncology.2018; 15(4): 234.     CrossRef
  • Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells
    Sung Ho Kim, Hyo Soon Yoo, Moon Kyung Joo, Taehyun Kim, Jong-Jae Park, Beom Jae Lee, Hoon Jai Chun, Sang Woo Lee, Young-Tae Bak
    BMC Cancer.2018;[Epub]     CrossRef
  • Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors
    Francisco Lopez-Tapia, Christine Brotherton-Pleiss, Peibin Yue, Heide Murakami, Ana Carolina Costa Araujo, Bruna Reis dos Santos, Erin Ichinotsubo, Anna Rabkin, Raj Shah, Megan Lantz, Suzie Chen, Marcus A. Tius, James Turkson
    ACS Medicinal Chemistry Letters.2018; 9(3): 250.     CrossRef
  • Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy
    Mario M. Soldevilla, Fernando Pastor
    Molecular Therapy.2018; 26(3): 675.     CrossRef
  • Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
    Jenny D. Beebe, Jing-Yuan Liu, Jian-Ting Zhang
    Pharmacology & Therapeutics.2018; 191: 74.     CrossRef
  • Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
    Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence, John J O’Shea
    Journal of Leukocyte Biology.2018; 104(3): 499.     CrossRef
  • Targeting JAK-STAT signal transduction in IBD
    Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen
    Pharmacology & Therapeutics.2018; 192: 100.     CrossRef
  • “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
    Emira Bousoik, Hamidreza Montazeri Aliabadi
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
    Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
    Ilenia Segatto, Gustavo Baldassarre, Barbara Belletti
    International Journal of Molecular Sciences.2018; 19(9): 2818.     CrossRef
  • Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors
    Masaki Miura, Takeshi Miyatsuka, Takehiro Katahira, Shugo Sasaki, Luka Suzuki, Miwa Himuro, Yuya Nishida, Yoshio Fujitani, Taka-aki Matsuoka, Hirotaka Watada
    EBioMedicine.2018; 36: 358.     CrossRef
  • Aptamer-iRNAs as Therapeutics for Cancer Treatment
    Mario M. Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P. Menon, Fernando Pastor
    Pharmaceuticals.2018; 11(4): 108.     CrossRef
  • A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
    Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M
    The Oncologist.2018; 23(6): 658.     CrossRef
  • Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome
    Konstantin Masliantsev, Baptiste Pinel, Anaïs Balbous, Pierre-Olivier Guichet, Gaëlle Tachon, Serge Milin, Julie Godet, Mathilde Duchesne, Antoine Berger, Christos Petropoulos, Michel Wager, Lucie Karayan-Tapon
    Oncotarget.2018; 9(3): 3968.     CrossRef
  • Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking
    Wenying Yu, Chenglong Li, Wenda Zhang, Yuanzheng Xia, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, Lingyi Kong
    Journal of Medicinal Chemistry.2017; 60(7): 2718.     CrossRef
  • Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
    Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
    npj Precision Oncology.2017;[Epub]     CrossRef
  • Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
    Davide Genini, Lara Brambilla, Erik Laurini, Jessica Merulla, Gianluca Civenni, Shusil Pandit, Rocco D'Antuono, Laurent Perez, David E. Levy, Sabrina Pricl, Giuseppina M. Carbone, Carlo V. Catapano
    Proceedings of the National Academy of Sciences.2017;[Epub]     CrossRef
  • Identification of novel small molecules that inhibit STAT3-dependent transcription and function
    Iryna Kolosenko, Yasmin Yu, Sander Busker, Matheus Dyczynski, Jianping Liu, Martin Haraldsson, Caroline Palm Apergi, Thomas Helleday, Katja Pokrovskaja Tamm, Brent D. G. Page, Dan Grander, Aamir Ahmad
    PLOS ONE.2017; 12(6): e0178844.     CrossRef
  • Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia
    Hui-Er Gao, Yue Sun, Ya-Hui Ding, Jing Long, Xiao-Lei Liu, Ming Yang, Qing Ji, Ying-Hui Li, Yue Chen, Quan Zhang, Ying-Dai Gao
    Oncotarget.2017; 8(24): 38990.     CrossRef
  • Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation
    Verena Leidgens, Judith Proske, Lisa Rauer, Sylvia Moeckel, Kathrin Renner, Ulrich Bogdahn, Markus J. Riemenschneider, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau, Corinna Seliger
    Oncotarget.2017; 8(5): 8250.     CrossRef
  • Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
    Yu Dong, Takuya Furuta, Hemragul Sabit, Tomohiro Kitabayashi, Shabierjiang Jiapaer, Masahiko Kobayashi, Yasushi Ino, Tomoki Todo, Lei Teng, Atsushi Hirao, Shi-Guang Zhao, Mitsutoshi Nakada
    Oncotarget.2017; 8(67): 111728.     CrossRef
  • Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
    Chengguang Zhao, Huameng Li, Huey-Jen Lin, Shulin Yang, Jiayuh Lin, Guang Liang
    Trends in Pharmacological Sciences.2016; 37(1): 47.     CrossRef
  • Targeting transcription factor STAT3 for cancer prevention and therapy
    Edna Zhi Pei Chai, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Chao Wang, Alan Prem Kumar, Ramar Perumal Samy, Lina H.K. Lim, Lingzhi Wang, Boon Cher Goh, Kwang Seok Ahn, Kam Man Hui, Gautam Sethi
    Pharmacology & Therapeutics.2016; 162: 86.     CrossRef
  • Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
    Chiara Lazzari, Alberto Verlicchi, Anastasios Gkountakos, Sara Pilotto, Mariacarmela Santarpia, Imane Chaib, Jose Luis Ramirez Serrano, Santiago Viteri, Daniela Morales-Espinosa, Claudio Dazzi, Filippo de Marinis, Peng Cao, Niki Karachaliou, Rafael Rosell
    Pulmonary Therapy.2016; 2(1): 1.     CrossRef
  • Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
    Zilma Escobar, Anders Bjartell, Giacomo Canesin, Susan Evans-Axelsson, Olov Sterner, Rebecka Hellsten, Martin H Johansson
    Journal of Medicinal Chemistry.2016; 59(10): 4551.     CrossRef
  • A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
    Andres Rojas, Pingyu Zhang, Ying Wang, Wai Chin Foo, Nina M. Muñoz, Lianchun Xiao, Jing Wang, Gregory J. Gores, Mien-Chie Hung, Boris Blechacz
    Neoplasia.2016; 18(6): 371.     CrossRef
  • Novel STAT 3 inhibitors for treating gastric cancer
    Catherine Cafferkey, Ian Chau
    Expert Opinion on Investigational Drugs.2016; 25(9): 1023.     CrossRef
  • ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
    I De Kouchkovsky, M Abdul-Hay
    Blood Cancer Journal.2016; 6(7): e441.     CrossRef
  • Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
    Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
    World Journal of Gastroenterology.2016; 22(19): 4638.     CrossRef
  • Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
    Malgorzata Szelag, Anna Piaszyk-Borychowska, Martyna Plens-Galaska, Joanna Wesoly, Hans A.R. Bluyssen
    Oncotarget.2016; 7(30): 48788.     CrossRef
  • Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt
    Maximilian Niit, Victoria Hoskin, Esther Carefoot, Mulu Geletu, Rozanne Arulanandam, Bruce Elliott, Leda Raptis
    Biomolecular Concepts.2015; 6(5-6): 383.     CrossRef
  • Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma
    Takuji Okusaka, Hideki Ueno, Masafumi Ikeda, Shuichi Mitsunaga, Masato Ozaka, Hiroshi Ishii, Osamu Yokosuka, Yoshihiko Ooka, Ryo Yoshimoto, Yasuo Yanagihara, Kiwamu Okita
    Hepatology Research.2015; 45(13): 1283.     CrossRef
  • STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
    Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer
    Cancer Research.2015; 75(18): 3812.     CrossRef
  • 18,599 View
  • 253 Download
  • 94 Web of Science
  • 96 Crossref
Close layer
Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study
Mee-Yon Cho, Joon Mee Kim, Jin Hee Sohn, Mi-Jung Kim, Kyoung-Mee Kim, Woo Ho Kim, Hyunki Kim, Myeong-Cherl Kook, Do Youn Park, Jae Hyuk Lee, HeeKyung Chang, Eun Sun Jung, Hee Kyung Kim, So-Young Jin, Joon Hyuk Choi, Mi Jin Gu, Sujin Kim, Mi Seon Kang, Chang Ho Cho, Moon-Il Park, Yun Kyung Kang, Youn Wha Kim, Sun Och Yoon, Han Ik Bae, Mee Joo, Woo Sung Moon, Dae Young Kang, Sei Jin Chang
Cancer Res Treat. 2012;44(3):157-165.   Published online September 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.3.157
AbstractAbstract PDFPubReaderePub
PURPOSE
As a result of various independently proposed nomenclatures and classifications, there is confusion in the diagnosis and prediction of biological behavior of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A comprehensive nationwide study is needed in order to understand the biological characteristics of GEP-NETs in Korea.
MATERIALS AND METHODS
We collected 4,951 pathology reports from 29 hospitals in Korea between 2000 and 2009. Kaplan-Meier survival analysis was used to determine the prognostic significance of clinicopathological parameters.
RESULTS
Although the GEP-NET is a relatively rare tumor in Korea, its incidence has increased during the last decade, with the most significant increase found in the rectum. The 10-year survival rate for well-differentiated endocrine tumor was 92.89%, in contrast to 85.74% in well differentiated neuroendocrine carcinoma and 34.59% in poorly differentiated neuroendocrine carcinoma. Disease related death was most common in the biliary tract (62.2%) and very rare in the rectum (5.2%). In Kaplan-Meier survival analysis, tumor location, histological classification, extent, size, mitosis, Ki-67 labeling index, synaptophysin expression, lymphovascular invasion, perineural invasion, and lymph node metastasis showed prognostic significance (p<0.05), however, chromogranin expression did not (p=0.148). The 2000 and 2010 World Health Organization (WHO) classification proposals were useful for prediction of the prognosis of GEP-NET.
CONCLUSION
The incidence of GEP-NET in Korea has shown a remarkable increase during the last decade, however, the distribution of tumors in the digestive system differs from that of western reports. Assessment of pathological parameters, including immunostaining, is crucial in understanding biological behavior of the tumor as well as predicting prognosis of patients with GEP-NET.

Citations

Citations to this article as recorded by  
  • Risk Factor Analysis of Lymph Node Metastasis for Rectal Neuroendocrine Tumors: Who Needs a Radical Resection in Rectal Neuroendocrine Tumors Sized 1–2 cm?
    Jin Sun Choi, Min Jung Kim, Rumi Shin, Ji Won Park, Seung Chul Heo, Seung-Yong Jeong, Kyu Joo Park, Seung-Bum Ryoo
    Annals of Surgical Oncology.2024; 31(4): 2414.     CrossRef
  • Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors
    Joo Young Kim, Jisup Kim, Yong-il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
    Scientific Reports.2024;[Epub]     CrossRef
  • Endoscopic mucosal resection using anchored snare Tip-in versus precut technique for small rectal neuroendocrine tumors
    Seung Wook Hong, Dong-Hoon Yang, Yoo Jin Lee, Dong Hoon Baek, Jaeyoung Chun, Hyun Gun Kim, Sung Joo Kim, Seung-Mo Hong, Dae-Seong Myung
    The Korean Journal of Internal Medicine.2024; 39(2): 238.     CrossRef
  • Assessing risk stratification in long-term outcomes of rectal neuroendocrine tumors following endoscopic resection: a multicenter retrospective study
    Hyun Jin Lee, Yun Seo, Chang Kyo Oh, Ji Min Lee, Hyun Ho Choi, Tae-Geun Gweon, Sung-Hak Lee, Dae Young Cheung, Jin Il Kim, Soo-Heon Park, Han Hee Lee
    Scandinavian Journal of Gastroenterology.2024; 59(7): 868.     CrossRef
  • Clinicopathological Characteristics, Survival and Prognostic Factors in Gastrointestinal Large Cell Neuroendocrine Carcinoma
    Lele Chang, Xuemei Zhang, Jiaxin Li, Qingwei Li
    American Journal of Clinical Oncology.2024; 47(8): 363.     CrossRef
  • Comparison of endoscopic resection therapies for rectal neuroendocrine tumors
    Meijiao Lu, Hongxia Cui, Mingjie Qian, Yating Shen, Jianhong Zhu
    Minimally Invasive Therapy & Allied Technologies.2024; 33(4): 207.     CrossRef
  • Klinische Bedeutung von neuroendokrinen Tumoren
    Philipp E. Hartrampf, Sebastian E. Serfling, Takahiro Higuchi, Jörg Bojunga, Alexander Weich, Rudolf A. Werner
    Die Radiologie.2024; 64(7): 536.     CrossRef
  • Mixed neuroendocrine–non-neuroendocrine neoplasm of the bile duct with long-term prognosis after neoadjuvant chemotherapy
    Shinya Nakamura, Masahiro Serikawa, Yasutaka Ishii, Yumiko Tatsukawa, Juri Ikemoto, Sayaka Miyamoto, Kenichiro Uemura, Shinya Takahashi, Koji Arihiro, Shiro Oka
    Clinical Journal of Gastroenterology.2024; 17(4): 717.     CrossRef
  • Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers
    Luigi Asmundo, Francesco Rizzetto, Michael Blake, Mark Anderson, Amirkasra Mojtahed, William Bradley, Anuradha Shenoy-Bhangle, Carlos Fernandez-del Castillo, Motaz Qadan, Cristina Ferrone, Jeffrey Clark, Valentina Ambrosini, Maria Picchio, Paola Mapelli,
    Journal of Clinical Medicine.2024; 13(11): 3281.     CrossRef
  • Primary coexisting adenocarcinoma of the colon and neuroendocrine tumor of the duodenum: A case report and review of the literature
    Song Fei, Wei-Dong Wu, Han-Shuo Zhang, Shao-Jie Liu, Dan Li, Bo Jin
    World Journal of Gastrointestinal Surgery.2024; 16(8): 2724.     CrossRef
  • Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios
    Katerina S. Konstantinoff, Ajaykumar C. Morani, Thomas A. Hope, Priya R. Bhosale, Isaac R. Francis, Motoyo Yano, Amir Iravani, Nikolaos A. Trikalinos, Malak Itani
    Abdominal Radiology.2023; 48(5): 1843.     CrossRef
  • Is lymphatic invasion of microrectal neuroendocrine tumors an incidental event?: A case report
    Jing-Xue Ran, Liang-Bi Xu, Wan-Wei Chen, Hao-Yi Yang, Yan Weng, Yong-Mei Peng
    World Journal of Clinical Cases.2023; 11(4): 859.     CrossRef
  • Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs
    Hyung Kyu Park, Ghee Young Kwon
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells
    Hirofumi Watanabe, Fumiyoshi Fujishima, Michiaki Unno, Hironobu Sasano, Takashi Suzuki
    Pathology - Research and Practice.2023; 244: 154418.     CrossRef
  • Different miRNAs Related to FBXW7 Mutations or High Mitotic Indices Contribute to Rectal Neuroendocrine Tumors: A Pilot Study
    Ho Suk Kang, Ha Young Park, Hyun Lim, Il Tae Son, Min-Jeong Kim, Nan Young Kim, Min Jeong Kim, Eun Sook Nam, Seong Jin Cho, Mi Jung Kwon
    International Journal of Molecular Sciences.2023; 24(7): 6329.     CrossRef
  • High-Grade Pure Esophageal Neuroendocrine Carcinoma Arising From Barrett’s Mucosa: A Rare Phenomenon
    Parth Patel, Eli A Zaher, Hasan Sqour
    Cureus.2023;[Epub]     CrossRef
  • Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors
    Jisup Kim, Dong-Hoon Yang, HaeSung Jung, HyungJun Cho, Hyeung-Jin Jang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2023; 147(7): 797.     CrossRef
  • Understanding the increasing incidence of neuroendocrine tumors
    Surabhi Pathak, Jason S. Starr, Thorvardur Halfdanarson, Mohamad Bassam Sonbol
    Expert Review of Endocrinology & Metabolism.2023; 18(5): 377.     CrossRef
  • Pancreatic Neuroendocrine Tumor (Pan-NET) Presented by Abdominal Pain: A Case Report and Literature Review
    Matteo Regolo, Nicolas Cardaci, Clara Salmeri, Alfredo Laudani, Michele Colaci, Massimo Ippolito, Fabio Motta, Salvatore Magrì, Stefanie Parisi, Alfredo Gaetano Torcitto, Lorenzo Malatino
    Journal of Clinical Medicine.2023; 12(20): 6617.     CrossRef
  • Clinical Value of Clip-and-Snare Assisted Endoscopic Submucosal Resection in Treatment of Rectal Neuroendocrine Tumors
    Xin-Tong Jiang, Yang Hu, Jian Gong, Shi-Bin Guo
    Visceral Medicine.2023; 39(5): 140.     CrossRef
  • Clinicopathological characteristics of extrahepatic biliary neuroendocrine neoplasms in the gallbladder, extrahepatic biliary tract, and ampulla of Vater: A single-center cross-sectional study
    Young Mok Park, Hyung Il Seo, Byeong Gwan Noh, Suk Kim, Seung Baek Hong, Nam Kyung Lee, Dong Uk Kim, Sung Yong Han
    Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(4): 380.     CrossRef
  • Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?
    Jack Cope, Raj Srirajaskanthan
    Current Oncology Reports.2022; 24(3): 257.     CrossRef
  • Clinicopathologic Characteristics of Gastroenteropancreatic Neuroendocrine Tumors: Experience of a National Referral Hospital in Indonesia
    Marini Stephanie, Nur Rahadiani, Hasan Maulahela, Ridho Ardhi Syaiful, Diah Rini Handjari, Ening Krisnuhoni
    Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 101.     CrossRef
  • Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms
    Daisuke Takayanagi, Hourin Cho, Erika Machida, Atsushi Kawamura, Atsuo Takashima, Satoshi Wada, Takuya Tsunoda, Takashi Kohno, Kouya Shiraishi
    Cancers.2022; 14(5): 1119.     CrossRef
  • Neuroendocrine Tumors: a Relevant Clinical Update
    Emma N. Rizen, Alexandria T. Phan
    Current Oncology Reports.2022; 24(6): 703.     CrossRef
  • A small, low-grade rectal neuroendocrine tumor with lateral pelvic lymph node metastasis: a case report
    Seonhui Shin, Young-In Maeng, Seyun Jung, Chun-Seok Yang
    Annals of Coloproctology.2022; 38(4): 327.     CrossRef
  • Rectal neuroendocrine neoplasms: what the radiologists should know
    Mayur Virarkar, Dheeraj R. Gopireddy, Ajaykumar C. Morani, Ahmad Alkhasawneh, Sergio Piotr Klimkowski, Sindhu Kumar, Chandana Lall, Priya Bhosale
    Abdominal Radiology.2022; 47(12): 4016.     CrossRef
  • Risk Factors for Lymph Node Metastasis and Oncologic Outcomes in Small Rectal Neuroendocrine Tumors with Lymphovascular Invasion
    Seung-Joo Nam, Byung Chang Kim, Hee Jin Chang, Han Ho Jeon, Junho Kim, Su Young Kim
    Gut and Liver.2022; 16(2): 228.     CrossRef
  • Clinical related factors to neuroendocrine tumors in Ecuadorian patients: a logistic biplot approach
    Karime Montes Escobar, José Luis Vicente Villardón, Daniel Fabricio Alarcón Cano, Aline Siteneski
    Investigación Clínica.2022; 63(1): 19.     CrossRef
  • Clinicopathological Characteristics of Gastroenteropancreatic Neuroendocrine Tumors
    Mustafa Şentürk, Berkan Acar, Mehmet Aykut Yildirim, Murat Çakir, Tevfik Küçükkartallar, Celalettin Vatansev
    Pancreas.2022; 51(2): 159.     CrossRef
  • Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 – 2015
    Tomonobu Koizumi, Kengo Otsuki, Yuriko Tanaka, Shintaro Kanda
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors
    Apostolis Papaefthymiou, Faidon-Marios Laskaratos, Apostolos Koffas, Anastasios Manolakis, Paraskevas Gkolfakis, Sergio Coda, Mikael Sodergren, Noriko Suzuki, Christos Toumpanakis
    Current Treatment Options in Oncology.2022; 23(7): 1014.     CrossRef
  • Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population‐based study
    Chuyan Chen, Haiyi Hu, Zhibo Zheng, Yi Yang, Wei Chen, Xinwei Qiao, Peng Li, Shutian Zhang
    Cancer Medicine.2022; 11(24): 4935.     CrossRef
  • Underwater endoscopic mucosal resection for rectal neuroendocrine tumors (with videos): a single center retrospective study
    Haitao Shi, Chuying Wang, Jie Wu, Bin Qin, Jiong Jiang, Na Liu, Yahua Song, Yun Qin, Shiyang Ma
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Endoscopic treatment for rectal neuroendocrine tumor: which method is better?
    Seung Min Hong, Dong Hoon Baek
    Clinical Endoscopy.2022; 55(4): 496.     CrossRef
  • Clinical outcomes of gastroduodenal neuroendocrine tumors according to their WHO grade: A single-institutional retrospective analysis
    Dae Gon Ryu, Su Jin Kim, Cheol Woong Choi, Dae Hwan Kang, Hyung Wook Kim, Su Bum Park, Hyeong Seok Nam, Si Hak Lee, Sun Hwi Hwang
    Medicine.2022; 101(37): e30397.     CrossRef
  • Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas
    Jing Chen, Yibing Liu, Ke Xu, Fei Ren, Bowen Li, Hong Sun
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study
    Benjamin E. White, Brian Rous, Kandiah Chandrakumaran, Kwok Wong, Catherine Bouvier, Mieke Van Hemelrijck, Gincy George, Beth Russell, Rajaventhan Srirajaskanthan, John K. Ramage
    The Lancet Regional Health - Europe.2022; 23: 100510.     CrossRef
  • The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
    Zhengqi Wu, Xiaotong Qiu, Yao Zhi, Xiaoju Shi, Guoyue Lv
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • MODERN PATHOLOGICAL CONSTELLATION FOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS AND IMMUNOHISTOCHEMICAL PANEL
    P. Vladova
    Trakia Journal of Sciences.2022; 20(4): 346.     CrossRef
  • An esophageal submucosal tumor treated with submucosal tunneling endoscopic resection: an unexpected result
    Ming-Yan Cai, Mariana Ferreira Cardoso, Yan Zhu, Yun-Shi Zhong, Ping-Hong Zhou
    Gastroenterology Report.2021; 9(3): 269.     CrossRef
  • A systematic review of chromogranin A (CgA) and its biomedical applications, unveiling its structure-related functions
    Kyuhyung Choi, Manhyuk Han, Seung Joong Kim
    Journal of the Korean Physical Society.2021; 78(5): 427.     CrossRef
  • Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor
    Min Je Sung, Moon Jae Chung
    The Korean Journal of Pancreas and Biliary Tract.2021; 26(1): 24.     CrossRef
  • Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
    Satya Das, Arvind Dasari
    Current Oncology Reports.2021;[Epub]     CrossRef
  • Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
    Anna La Salvia, Paula Espinosa-Olarte, Maria Del Carmen Riesco-Martinez, Beatriz Anton-Pascual, Rocío Garcia-Carbonero
    Cancers.2021; 13(7): 1701.     CrossRef
  • Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
    Changhoon Yoo, Chung Ryul Oh, Seung-Tae Kim, Woo Kyun Bae, Hye-Jin Choi, Do-Youn Oh, Myung-Ah Lee, Baek-Yeol Ryoo
    Cancer Research and Treatment.2021; 53(2): 291.     CrossRef
  • Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms
    Deng Han, Yuan-Liang Li, Zhi-Wei Zhou, Fei Yin, Jie Chen, Fang Liu, Yan-Fen Shi, Wei Wang, Yu Zhang, Xian-Jun Yu, Jian-Ming Xu, Run-Xiang Yang, Chao Tian, Jie Luo, Huang-Ying Tan
    World Journal of Gastroenterology.2021; 27(21): 2895.     CrossRef
  • Standardization of the pathologic diagnosis of appendiceal mucinous neoplasms
    Dong-Wook Kang, Baek-hui Kim, Joon Mee Kim, Jihun Kim, Hee Jin Chang, Mee Soo Chang, Jin-Hee Sohn, Mee-Yon Cho, So-Young Jin, Hee Kyung Chang, Hye Seung Han, Jung Yeon Kim, Hee Sung Kim, Do Youn Park, Ha Young Park, So Jeong Lee, Wonae Lee, Hye Seung Lee,
    Journal of Pathology and Translational Medicine.2021; 55(4): 247.     CrossRef
  • Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma
    Hualong Zheng, YaJun Zhao, Qingliang He, Hankun Hao, Yantao Tian, Bingbing Zou, Lixin Jiang, Xiantu Qiu, Yanbing Zhou, Zhi Li, Yanchang Xu, Gang Zhao, Fangqin Xue, Shuliang Li, Weihua Fu, Yongxiang Li, Xiaojun Zhou, Yong Li, Zhenggang Zhu, Jinping Chen, Z
    Gastric Cancer.2021; 24(2): 503.     CrossRef
  • Comparative study of laparoscopic versus open radical gastrectomy in advanced gastric neuroendocrine carcinoma: Analysis from a high-volume institution
    Ya-Jun Zhao, Lv-Ping Zhuang, Yi-Yang Liu, Ren-Cheng Chen, Jun Zhang, Hai-Xing Zhu, Yong-Cang Wang, Hao You, Ming-Wei Zhang, Xin-Yang He
    Asian Journal of Surgery.2020; 43(3): 488.     CrossRef
  • Potential Pitfalls in Diagnostic Digital Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal Neuroendocrine Tumors
    Sean M Hacking, Sujata Sajjan, Lili Lee, Yonah Ziemba, Mallorie Angert, Yihe Yang, Cao Jin, Hector Chavarria, Nidhi Kataria, Swachi Jain, Mansoor Nasim
    Pathology - Research and Practice.2020; 216(3): 152753.     CrossRef
  • Imaging and Contrast-enhanced Ultrasound features of duodenal neuroendocrine tumor: A case report
    Yan-Qun Zhang, Jie-Xian Wen, Rong-Kui Luo, Hai-Xia Yuan, Wen-Ping Wang
    Clinical Hemorheology and Microcirculation.2020; 76(1): 27.     CrossRef
  • Rare cancers are not rare in Asia as well: The rare cancer burden in East Asia
    Tomohiro Matsuda, Young-Joo Won, RuRu Chun-ju Chiang, Jiwon Lim, Kumiko Saika, Keisuke Fukui, Wen-Chung Lee, Laura Botta, Alice Bernasconi, Annalisa Trama
    Cancer Epidemiology.2020; 67: 101702.     CrossRef
  • Islet Tumors
    Tiffany J. Sinclair, George A. Poultsides
    Advances in Surgery.2020; 54: 69.     CrossRef
  • Primary Large Cell Neuroendocrine Carcinoma of the Esophagus Disguised as a Food Impaction
    Harsh D. Patel, Jared Beck, Archish Kataria, Glenn W. Gross, Juan Echavarria
    ACG Case Reports Journal.2020; 7(6): e00384.     CrossRef
  • Pancreatic nodule positive for 68-Ga-DOTAPEPTIDE-PET: NET or ectopic spleen? The importance of a good differential diagnosis
    Francesco Serra, Gianluca De Matteis, Sara Delfanti, Monica Feltri, Alessandro Vanoli, Giorgio Cavenaghi, Anna Gallotti, Marcello Maestri, Silvia Brugnatelli
    Clinical and Translational Imaging.2020; 8(5): 307.     CrossRef
  • Gastric neuroendocrine tumor with Helicobacter pylori-associated chronic gastritis
    Giovanni Serio, Armando Dell’Anna, Anna Debenedittis, Elisa Stasi, Maria Arcangela Cascarano
    International Journal of Surgery Case Reports.2020; 75: 361.     CrossRef
  • Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis
    Jisup Kim, Joo Young Kim, Eun Hye Oh, Changhoon Yoo, In Ja Park, Dong-Hoon Yang, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
    American Journal of Surgical Pathology.2020; 44(11): 1496.     CrossRef
  • Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours
    Yuan-Liang Li, Xu-Dong Qiu, Jie Chen, Yu Zhang, Jie Li, Jian-Ming Xu, Chao Wang, Zhi-Rong Qi, Jie Luo, Huang-Ying Tan
    World Journal of Gastrointestinal Oncology.2020; 12(12): 1416.     CrossRef
  • Clinicopathological Study of 100 Cases of Neuroendocrine Neoplasms of the Gastroenteropancreatic System: A Tertiary Cancer Center Experience
    Satarupa Tarak Nath Samanta, Shailee Paresh Bhai Mehta, Trupti S Patel, Dhaval H Jetly
    Indian Journal of Medical and Paediatric Oncology.2020; 41(03): 340.     CrossRef
  • Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification
    Haihong Wang, Yaobing Chen, Guoliang Pi, Ying Zhu, Shengli Yang, Hong Mei, Zhenyu Lin, Tao Zhang
    Oncology Letters.2020;[Epub]     CrossRef
  • Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis
    Junho Kang, Changhoon Yoo, Hee-Sang Hwang, Seung-Mo Hong, Kyu-pyo Kim, Sun Young Kim, Yong-Sang Hong, Tae Won Kim, Baek-Yeol Ryoo
    Investigational New Drugs.2019; 37(4): 763.     CrossRef
  • A rare rarity: Neuroendocrine tumor of the esophagus
    Elisa Giannetta, Valentina Guarnotta, Francesca Rota, Federica de Cicco, Federica Grillo, Annamaria Colao, Antongiulio Faggiano
    Critical Reviews in Oncology/Hematology.2019; 137: 92.     CrossRef
  • Preoperative diagnosis of well‐differentiated neuroendocrine tumor in common hepatic duct by brush cytology: A case report
    Jiwoon Choi, Kyong Joo Lee, Sung Hoon Kim, Mee‐Yon Cho
    Diagnostic Cytopathology.2019; 47(7): 720.     CrossRef
  • Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors
    Chang Min Cho
    The Korean Journal of Gastroenterology.2019; 73(3): 124.     CrossRef
  • Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
    Min-Wei Yang, Xue-Liang Fu, Yong-Sheng Jiang, Xiao-Jing Chen, Ling-Ye Tao, Jian-Yu Yang, Yan-Miao Huo, Wei Liu, Jun-Feng Zhang, Pei-Feng Liu, Qiang Liu, Rong Hua, Zhi-Gang Zhang, Yong-Wei Sun, De-Jun Liu
    World Journal of Gastroenterology.2019; 25(14): 1684.     CrossRef
  • Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors
    Kira Oleinikov, Alain Dancour, Julia Epshtein, Ariel Benson, Haggi Mazeh, Ilanit Tal, Shay Matalon, Carlos A Benbassat, Dan M Livovsky, Eran Goldin, David J Gross, Harold Jacob, Simona Grozinsky-Glasberg
    The Journal of Clinical Endocrinology & Metabolism.2019; 104(7): 2637.     CrossRef
  • Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single‐center study
    Lijie Song, Xuejia Zhai, Shunli Yu, Yihui Ma, Feng Wang, Xuxu Yu, Shuang Tao, Yujin Lian, Minjie Yang, Weili Tao, Qingxia Fan
    Cancer Medicine.2019; 8(8): 3729.     CrossRef
  • Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors
    Louis de Mestier, Diane Lorenzo, Caroline Fine, Jérôme Cros, Olivia Hentic, Thomas Walter, Yves Panis, Anne Couvelard, Guillaume Cadiot, Philippe Ruszniewski
    Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(5): 101293.     CrossRef
  • Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review
    Francesco Lancellotti, Luca Sacco, Saverio Cerasari, Vittoria Bellato, Simone Cicconi, Antonio Ciardi, Edoardo Maria Muttillo, Tiziana Feola, Roberto Caronna, Piero Chirletti
    World Journal of Surgical Oncology.2019;[Epub]     CrossRef
  • Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility
    Zhiyan Fu, Chunlai Zuo, Christine E. Sheehan, Deepa T. Patil, Jingmei Lin, Zhaohai Yang, Hwajeong Lee
    Applied Immunohistochemistry & Molecular Morphology.2019; 27(6): 454.     CrossRef
  • Duodenal neuroendocrine tumors
    A. V. Alekberzade, N. N. Krylov, T. N. Garmanova, R. Shahbazov, F. Azari, K. S. Zuykova, E. D. Litovchenko
    Khirurgiya. Zhurnal im. N.I. Pirogova.2019; (7): 87.     CrossRef
  • [68Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications
    Elisabetta Giovannini, Giampiero Giovacchini, Elisa Borsò, Patrizia Lazzeri, Mattia Riondato, Rossella Leoncini, Valerio Duce, Andrea Ciarmiello
    Current Radiopharmaceuticals.2019; 12(1): 11.     CrossRef
  • Multifocal G1-G2 gastric neuroendocrine tumors: Differentiating between Type I, II and III, a clinicopathologic review
    Khaled Algashaamy, Monica Garcia-Buitrago
    World Journal of Clinical Cases.2019; 7(17): 2413.     CrossRef
  • Establishment and characterization of a novel neuroendocrine carcinoma cell line derived from a human ascending colon tumor
    Seiichi Shinji, Norihiko Sasaki, Takeshi Yamada, Michihiro Koizumi, Ryo Ohta, Akihisa Matsuda, Yasuyuki Yokoyama, Goro Takahashi, Masahiro Hotta, Keisuke Hara, Kohki Takeda, Koji Ueda, Sho Kuriyama, Toshiyuki Ishiwata, Yoshibumi Ueda, Takashi Murakami, Yo
    Cancer Science.2019; 110(12): 3708.     CrossRef
  • Gastric neuroendocrine tumors
    A. V. Alekberzade, N. N. Krylov, E. M. Lipnitskiy, R. O. Shakhbazov, F. Azari
    Khirurgiya. Zhurnal im. N.I. Pirogova.2019; (12): 111.     CrossRef
  • Resectability of Rectal Neuroendocrine Tumors Using Endoscopic Mucosal Resection with a Ligation Band Device and Endoscopic Submucosal Dissection
    Hong Kyu Lim, Seong Jun Lee, Dong Hoon Baek, Do Youn Park, Bong Eun Lee, Eun Young Park, Joon Woo Park, Gwang Ha Kim, Geun Am Song
    Gastroenterology Research and Practice.2019; 2019: 1.     CrossRef
  • Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia
    David Wyld, Mark H. Wan, Julie Moore, Nathan Dunn, Philippa Youl
    Cancer Epidemiology.2019; 63: 101598.     CrossRef
  • Lymphovascular invasion as a prognostic value in small rectal neuroendocrine tumor treated by local excision: A systematic review and meta-analysis
    Ho Suk Kang, Mi Jung Kwon, Tae-Hwan Kim, Junhee Han, Young-Su Ju
    Pathology - Research and Practice.2019; 215(11): 152642.     CrossRef
  • Gastroenteropancreatic Neuroendocrine Tumor with Hepatic Metastasis Misdiagnosed as Hepatocellular Carcinoma
    Seul Ki Kim, Sang Chul Kim, Seok Gyo Seo, Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
    The Korean Journal of Medicine.2019; 94(5): 449.     CrossRef
  • Clinicopathologic Characteristics and Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasm in a Multi-Ethnic Asian Institution
    Wai Meng Tai, Sze Huey Tan, Damien Meng Yew Tan, Kelvin Siu Hoong Loke, David Chee Eng Ng, Sean Xuexian Yan, Jacqueline Siok Gek Hwang, Kiat Hon Lim, Lih Ming Loh, Peng Chin Kek, Brian Kim Poh Goh, Ser Yee Lee, Alexander Yaw Fui Chung, Simon Yew Kuang Ong
    Neuroendocrinology.2019; 108(4): 265.     CrossRef
  • Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center
    Constantinos Savva, Philip Kaye, Irshad Soomro, Simon L. Parsons, Eleanor James, Srinivasan Madhusudan
    Journal of Gastrointestinal Cancer.2018; 49(1): 85.     CrossRef
  • Transanal Endoscopic Microsurgery for Patients with Rare Rectal Tumors
    Xin Wu, Guole Lin, Huizhong Qiu, Jiaolin Zhou
    Journal of Laparoendoscopic & Advanced Surgical Techniques.2018; 28(5): 546.     CrossRef
  • A case of small intestinal neuroendocrine carcinoma diagnosed using double-balloon endoscopy with long-term survival
    Seiji Kawano, Yuichi Miyashima, Yoshio Miyabe, Yoshinari Kawai, Toshihiro Murata, Masashi Uda, Toshihiro Inokuchi, Hiroyuki Okada
    Clinical Journal of Gastroenterology.2018; 11(3): 240.     CrossRef
  • How should incidental NEN of the pancreas and gastrointestinal tract be followed?
    Riccardo Ariotti, Stefano Partelli, Francesca Muffatti, Valentina Andreasi, Francesca Della Sala, Massimo Falconi
    Reviews in Endocrine and Metabolic Disorders.2018; 19(2): 139.     CrossRef
  • Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors
    Min Jeong Kim, Mi Jung Kwon, Ho Suk Kang, Kyung Chan Choi, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hyoung-Chul Park
    BioMed Research International.2018; 2018: 1.     CrossRef
  • A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms
    Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao
    Scientific Reports.2018;[Epub]     CrossRef
  • Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
    Lingaku Lee, Tetsuhide Ito, Robert T. Jensen
    Expert Opinion on Pharmacotherapy.2018; 19(8): 909.     CrossRef
  • Pancreatic Neuroendocrine Neoplasms: A Role of Laparoscopy in Surgical Treatment: Review
    Jacek Szeliga, Marek Jackowski
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(3): 147.     CrossRef
  • Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
    Panpan Zhang, Wei Wang, Ming Lu, Changqing Zeng, Jie Chen, Enxiao Li, Huangying Tan, Wei Wang, Xianjun Yu, Qiyun Tang, Jiemin Zhao, Lin Shen, Jie Li
    Cancer Medicine.2018; 7(9): 4361.     CrossRef
  • Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options
    Steven D. Colquhoun
    Liver Research.2018; 2(2): 92.     CrossRef
  • Endoscopic Treatment Outcome of Rectal Neuroendocrine Tumors Removed by Ligation-assisted Endoscopic Submucosal Resection
    Min Geun Gu, Si Hyung Lee
    The Korean Journal of Gastroenterology.2018; 72(3): 128.     CrossRef
  • Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population‐based study
    Fang‐Xi Tian, Yu‐Qing Cai, Lv‐Ping Zhuang, Ming‐Fang Chen, Zhong‐Biao Xiu, Yi Zhang, Hong Liu, Zhi‐Hong Liu, Guo‐Ping Liu, Chen Zeng, Fei‐Ling Lin, Jing Liu, Si‐Ting Huang, Liang‐Zhi Zhang, Hua‐Yang Lin
    Cancer Medicine.2018; 7(11): 5359.     CrossRef
  • Global burden of neuroendocrine tumors and changing incidence in Kentucky
    Aman Chauhan, Qian Yu, Neha Ray, Zainab Farooqui, Bin Huang, Eric B. Durbin, Thomas Tucker, Mark Evers, Susanne Arnold, Lowell B. Anthony
    Oncotarget.2018; 9(27): 19245.     CrossRef
  • Gastroenteropancreatic neuroendocrine tumor registry study in China
    Lin Cong, Wenming Wu, Wenhui Lou, Jinwan Wang, Feng Gu, Jiaming Qian, Jianming Xu, Feng Bi, Sanjun Cai, Chengwei Tang, Yulong He, Jie Zhong, Yupei Zhao
    Journal of Pancreatology.2018; 1(1): 35.     CrossRef
  • Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience
    Chul-Hyun Lim, In Seok Lee, Byoung Yeon Jun, Jin Su Kim, Yu Kyung Cho, Jae Myung Park, Sang Young Roh, Myung Ah Lee, Sang Woo Kim, Myung-Gyu Choi
    The Korean Journal of Internal Medicine.2017; 32(3): 452.     CrossRef
  • Uncommon Anal Neoplasms
    Amitesh C. Roy, David Wattchow, David Astill, Simron Singh, Susan Pendlebury, Kirsten Gormly, Eva Segelov
    Surgical Oncology Clinics of North America.2017; 26(1): 143.     CrossRef
  • Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors
    Wenhao Ge, Dongkai Zhou, Shaoyan Xu, Weilin Wang, Shusen Zheng
    International Journal of Surgery.2017; 39: 127.     CrossRef
  • Recent updates on grading and classification of neuroendocrine tumors
    Joo Young Kim, Seung-Mo Hong, Jae Y. Ro
    Annals of Diagnostic Pathology.2017; 29: 11.     CrossRef
  • Mixed adenoneuroendocrine carcinoma derived from the cystic duct: A case report
    Yu-ki Takemoto, Tomoyuki Abe, Hironobu Amano, Keiji Hanada, Akihito Okazaki, Tomoyuki Minami, Tsuyoshi Kobayashi, Masahiro Nakahara, Shuji Yonehara, Hideki Ohdan, Toshio Noriyuki
    International Journal of Surgery Case Reports.2017; 39: 29.     CrossRef
  • Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
    Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
    Journal of Pathology and Translational Medicine.2017; 51(4): 388.     CrossRef
  • Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
    Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee
    Cancer Chemotherapy and Pharmacology.2017; 80(4): 799.     CrossRef
  • Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas
    De-Jun Liu, Xue-Liang Fu, Wei Liu, Lu-Ying Zheng, Jun-Feng Zhang, Yan-Miao Huo, Jiao Li, Rong Hua, Qiang Liu, Yong-Wei Sun
    World Journal of Gastroenterology.2017; 23(3): 516.     CrossRef
  • Is endoscopic ultrasonography essential for endoscopic resection of small rectal neuroendocrine tumors?
    Su Bum Park, Dong Jun Kim, Hyung Wook Kim, Cheol Woong Choi, Dae Hwan Kang, Su Jin Kim, Hyeong Seok Nam
    World Journal of Gastroenterology.2017; 23(11): 2037.     CrossRef
  • Predictive Factors for Lymph Node Metastasis and Prognostic Factors for Survival in Rectal Neuroendocrine Tumors
    Beonghoon Sohn, Yoomin Kwon, Seung-Bum Ryoo, Inho Song, Yoon-Hye Kwon, Dong Woon Lee, Sang Hui Moon, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park
    Journal of Gastrointestinal Surgery.2017; 21(12): 2066.     CrossRef
  • Efficacy of Precut Endoscopic Mucosal Resection for Treatment of Rectal Neuroendocrine Tumors
    Hoonsub So, Su Hyun Yoo, Seungbong Han, Gwang-un Kim, Myeongsook Seo, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon
    Clinical Endoscopy.2017; 50(6): 585.     CrossRef
  • Gastroenteropancreatic—origin neuroendocrine carcinomas
    Yong Gyun Won, Kyung-Jin Seo, Jiyeon Hyeon, Ok Ran Shin, Eundeok Chang, Der Sheng Sun, Hae Sung Won, Yoon Ho Ko, Sae Jung Na, Su Lim Lee, Young Mi Ku, Dong Soo Lee
    Medicine.2017; 96(49): e9009.     CrossRef
  • Sex comb on midleg like-2 is a novel specific marker for the diagnosis of gastroenteropancreatic neuroendocrine tumors
    Jiao-Jiao Yang, Hua Huang, Ming-Bing Xiao, Feng Jiang, Wen-Kai Ni, Yi-Fei Ji, Cui-Hua Lu, Run-Zhou Ni
    Experimental and Therapeutic Medicine.2017; 14(2): 1749.     CrossRef
  • A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china
    Jin-Hu Fan, Yu-Qing Zhang, Su-Sheng Shi, Yuan-Jia Chen, Xing-Hua Yuan, Li-Ming Jiang, Shao-Ming Wang, Li Ma, Yu-Tong He, Chang-Yan Feng, Xi-Bin Sun, Qing Liu, Katrina Deloso, Yihebali Chi, You-Lin Qiao
    Oncotarget.2017; 8(42): 71699.     CrossRef
  • Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
    Jie Li, Ming Lu, Zhihao Lu, Zhongwu Li, Yiqiang Liu, Li Yang, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Jifang Gong, Jing Gao, Yan Li, Lin Shen
    Oncotarget.2017; 8(15): 25669.     CrossRef
  • Cap-assisted EMR for rectal neuroendocrine tumors: comparisons with conventional EMR and endoscopic submucosal dissection (with videos)
    Dong-Hoon Yang, Yangsoon Park, Sang Hyoung Park, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Gastrointestinal Endoscopy.2016; 83(5): 1015.     CrossRef
  • Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
    Sven-Petter Haugvik, Eva Tiensuu Janson, Pia Österlund, Seppo W. Langer, Ragnhild Sørum Falk, Knut Jørgen Labori, Lene Weber Vestermark, Henning Grønbæk, Ivar Prydz Gladhaug, Halfdan Sorbye
    Annals of Surgical Oncology.2016; 23(5): 1721.     CrossRef
  • Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center
    Jeung Hui Pyo, Sung Noh Hong, Byung-Hoon Min, Jun Haeng Lee, Dong Kyung Chang, Poong-Lyul Rhee, Jae Jun Kim, Sun Kyu Choi, Sin-Ho Jung, Hee Jung Son, Young-Ho Kim
    Journal of Gastroenterology.2016; 51(12): 1112.     CrossRef
  • Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
    Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2016; 140(5): 437.     CrossRef
  • Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
    C. De Divitiis, C. von Arx, A. M. Grimaldi, D. Cicala, F. Tatangelo, A. Arcella, G. M. Romano, E. Simeone, R. V. Iaffaioli, P. A. Ascierto, S. Tafuto
    Journal of Translational Medicine.2016;[Epub]     CrossRef
  • Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution
    Lin-Jie Guo, Chun-Hui Wang, Cheng-Wei Tang
    Asia-Pacific Journal of Clinical Oncology.2016; 12(3): 284.     CrossRef
  • The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution
    Seung Tae Kim, Sang Yun Ha, Jeeyun Lee, Sung No Hong, Dong Kyung Chang, Young Ho Kim, Yoon Ah Park, Jung Wook Huh, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Hee Cheol Kim, Young Suk Park
    Medicine.2016; 95(19): e3534.     CrossRef
  • Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience
    Govind Babu Kanakasetty, Loknatha Dasappa, Kuntegowdanahalli Chinnagiriyappa Lakshmaiah, Mangesh Kamath, Linu Abraham Jacob, Suresh Babu Mallekavu, Lakkavalli Krishnappa Rajeev, Rudresha Antapura Haleshappa, Lokesh Kadabur Nagendrappa, Smitha Carol Saldan
    Journal of Oncology.2016; 2016: 1.     CrossRef
  • Endoscopic treatments for rectal neuroendocrine tumors smaller than 16 mm: a meta-analysis
    Hai-Ping Zhang, Wei Wu, Sheng Yang, Jun Lin
    Scandinavian Journal of Gastroenterology.2016; 51(11): 1345.     CrossRef
  • Lymph node size is not a reliable criterion for predicting nodal metastasis in rectal neuroendocrine tumours
    B. C. Kim, Y. E. Kim, H. J. Chang, S. H. Lee, E. G. Youk, D.‐S. Lee, J. B. Lee, E.‐J. Lee, M. J. Kim, D. K. Sohn, J. H. Oh
    Colorectal Disease.2016;[Epub]     CrossRef
  • Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors
    Jae Hee Cho, Ji Kon Ryu, Si Young Song, Jin-Hyeok Hwang, Dong Ki Lee, Sang Myung Woo, Young-Eun Joo, Seok Jeong, Seung-Ok Lee, Byung Kyu Park, Young Koog Cheon, Jimin Han, Tae Nyeun Kim, Jun Kyu Lee, Sung-Hoon Moon, Hyunjin Kim, Eun Taek Park, Jae Chul Hw
    Pancreas.2016; 45(7): 941.     CrossRef
  • Endoscopic Resection for Small Rectal Neuroendocrine Tumors: Comparison of Endoscopic Submucosal Resection with Band Ligation and Endoscopic Submucosal Dissection
    Byoung Wook Bang, Jin Seok Park, Hyung Kil Kim, Yong Woon Shin, Kye Sook Kwon, Joon Mee Kim
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
  • Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience
    Chaoyong Shen, Huijiao Chen, Haining Chen, Yuan Yin, Luyin Han, Jiaju Chen, Sumin Tang, Xiaonan Yin, Zongguang Zhou, Bo Zhang, Zhixin Chen
    BMC Gastroenterology.2016;[Epub]     CrossRef
  • The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure
    Yoichiro Okubo, Osamu Motohashi, Norisuke Nakayama, Ken Nishimura, Rika Kasajima, Yohei Miyagi, Manabu Shiozawa, Emi Yoshioka, Masaki Suzuki, Kota Washimi, Kae Kawachi, Madoka Nito, Yoichi Kameda, Tomoyuki Yokose
    Diagnostic Pathology.2016;[Epub]     CrossRef
  • A Case of Endoscopically Complete Remission of Esophageal Neuroendocrine Tumors by Concurrent Chemoradiation Therapy
    Myung Hee Kim, Hyun Yong Jeong, Jae Kyu Seong, Hee Seok Moon, Sun Hyung Kang, Duk Ki Kim
    The Korean Journal of Gastroenterology.2016; 68(5): 265.     CrossRef
  • Outcomes after local excision for rectal neuroendocrine tumor
    Yoomin Kwon, Seung-Bum Ryoo, Inho Song, Yoon-Hye Kwon, Dong Woon Lee, Sang Hui Moon, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park
    Korean Journal of Clinical Oncology.2016; 12(2): 104.     CrossRef
  • Multivariate analysis of metastasis-related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features
    Caiyun Tang, Lingqi Gong, Wenli Zou, Jie Zhang, Yuqian Zhou, Xiaoping Wu, Fanggen Lu, Chunhui Ouyang, Xiaowei Liu
    Oncology Reports.2016; 36(6): 3343.     CrossRef
  • Management of gastric and duodenal neuroendocrine tumors
    Yuichi Sato, Satoru Hashimoto, Ken-ichi Mizuno, Manabu Takeuchi, Shuji Terai
    World Journal of Gastroenterology.2016; 22(30): 6817.     CrossRef
  • Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)
    Kaizhou Jin, Jin Xu, Jie Chen, Minhu Chen, Rufu Chen, Ye Chen, Zhiyu Chen, Bin Cheng, Yihebali Chi, Shi-Ting Feng, Deliang Fu, Baohua Hou, Dan Huang, Heguang Huang, Qiang Huang, Jie Li, Ying Li, Houjie Liang, Rong Lin, An'an Liu, Jixi Liu, Xubao Liu, Ming
    International Journal of Oncology.2016; 49(5): 1991.     CrossRef
  • ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
    M. Falconi, B. Eriksson, G. Kaltsas, D.K. Bartsch, J. Capdevila, M. Caplin, B. Kos-Kudla, D. Kwekkeboom, G. Rindi, G. Klöppel, N. Reed, R. Kianmanesh, R.T. Jensen
    Neuroendocrinology.2016; 103(2): 153.     CrossRef
  • Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis
    Tetsuhide Ito, Hisato Igarashi, Kazuhiko Nakamura, Hironobu Sasano, Takuji Okusaka, Koji Takano, Izumi Komoto, Masao Tanaka, Masayuki Imamura, Robert T. Jensen, Ryoichi Takayanagi, Akira Shimatsu
    Journal of Gastroenterology.2015; 50(1): 58.     CrossRef
  • Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics
    Nurhee Hong, Hyoung Jung Kim, Jae Ho Byun, So Yeon Kim, Kyoung Won Kim, Jin Hee Kim, Seung-Mo Hong
    Abdominal Imaging.2015; 40(1): 181.     CrossRef
  • Circumferential submucosal incision prior to endoscopic mucosal resection provides comparable clinical outcomes to submucosal dissection for well-differentiated neuroendocrine tumors of the rectum
    Dae Young Cheung, Soo Kyoung Choi, Hyung-Keun Kim, Sung Soo Kim, Hiun-Suk Chae, Kyung Jin Seo, Young-Seok Cho
    Surgical Endoscopy.2015; 29(6): 1500.     CrossRef
  • Non-L-cell Immunophenotype and Large Tumor Size in Rectal Neuroendocrine Tumors Are Associated With Aggressive Clinical Behavior and Worse Prognosis
    Joo Young Kim, Ki-Suk Kim, Kyung-Jo Kim, In Ja Park, Jong Lyul Lee, Seung-Jae Myung, Yangsoon Park, Young Soo Park, Chang Sik Yu, Jin Cheon Kim, Eunsil Yu, Hyeung-Jin Jang, Seung-Mo Hong
    American Journal of Surgical Pathology.2015; 39(5): 632.     CrossRef
  • Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors
    Shunda Du, Jianjiao Ni, Linqian Weng, Fei Ma, Shaohua Li, Wenze Wang, Xinting Sang, Xin Lu, Shouxian Zhong, Yilei Mao
    Medicine.2015; 94(34): e1429.     CrossRef
  • Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute
    Yooju Shin, Sang Yun Ha, Jiyeon Hyeon, Boram Lee, Jeeyun Lee, Kee-Taek Jang, Kyoung-Mee Kim, Young Suk Park, Cheol-Keun Park
    Cancer Research and Treatment.2015; 47(4): 738.     CrossRef
  • Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters
    Jin Hee Sohn, Mee-Yon Cho, Yangsoon Park, Hyunki Kim, Woo Ho Kim, Joon Mee Kim, Eun Sun Jung, Kyoung-Mee Kim, Jae Hyuk Lee, Hee Kyung Chan, Do Youn Park, Mee Joo, Sujin Kim, Woo Sung Moon, Mi Seon Kang, So-Young Jin, Yun Kyung Kang, Sun Och Yoon, HyeSeung
    Cancer Research and Treatment.2015; 47(4): 813.     CrossRef
  • Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
    Emma Ilett, Seppo Langer, Ingrid Olsen, Birgitte Federspiel, Andreas Kjær, Ulrich Knigge
    Diagnostics.2015; 5(2): 119.     CrossRef
  • A Re-evaluation of Colorectal Neuroendocrine Tumors Based on WHO 2010
    Akira Watanabe, Mitsuyoshi Ota, Yusuke Suwa, Shinsuke Suzuki, Atsushi Ishibe, Jun Watanabe, Kazuteru Watanabe, Yasushi Ichikawa, Kingo Hirasawa, Mikiko Tanabe, Itaru Endo
    Nippon Daicho Komonbyo Gakkai Zasshi.2015; 68(2): 61.     CrossRef
  • Gastroenteropancreatic high‐grade neuroendocrine carcinoma
    Halfdan Sorbye, Jonathan Strosberg, Eric Baudin, David S. Klimstra, James C. Yao
    Cancer.2014; 120(18): 2814.     CrossRef
  • Mixed Large Cell Neuroendocrine Carcinoma and Adenocarcinoma with Spindle Cell and Clear Cell Features in the Extrahepatic Bile Duct
    John Wysocki, Rishi Agarwal, Laura Bratton, Jeremy Nguyen, Mandy Crause Weidenhaft, Nathan Shores, Hillary Z. Kimbrell
    Case Reports in Pathology.2014; 2014: 1.     CrossRef
  • Spectrum of Gastroenteropancreatic NENs in Routine Histological Examinations of Bioptic and Surgical Specimen: A Study of 161 Cases Collected from 17 Departments of Pathology in the Czech Republic
    Václav Mandys, Tomáš Jirásek
    Gastroenterology Research and Practice.2014; 2014: 1.     CrossRef
  • Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
    Franco Grimaldi, Nicola Fazio, Roberto Attanasio, Andrea Frasoldati, Enrico Papini, Francesco Angelini, Roberto Baldelli, Debora Berretti, Sara Bianchetti, Giancarlo Bizzarri, Marco Caputo, Roberto Castello, Nadia Cremonini, Anna Crescenzi, Maria Vittoria
    Journal of Endocrinological Investigation.2014; 37(9): 875.     CrossRef
  • Clinical features and management of type I gastric carcinoids
    Yuichi Sato
    Clinical Journal of Gastroenterology.2014; 7(5): 381.     CrossRef
  • Diagnosis and Treatment of Rectal Neuroendocrine Tumor
    Hyun Deok Shin
    Korean Journal of Medicine.2014; 87(4): 415.     CrossRef
  • Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study
    Xianbin Zhang, Li Ma, Haidong Bao, Jing Zhang, Zhongyu Wang, Peng Gong
    BMC Endocrine Disorders.2014;[Epub]     CrossRef
  • The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea
    Chang Geun Lee, Yun Jeong Lim, Seun Ja Park, Byung Ik Jang, Seok Reyol Choi, Jae Kwang Kim, Yong-Tae Kim, Joo Young Cho, Chang Hun Yang, Hoon Jai Chun, Si Young Song
    BMC Cancer.2014;[Epub]     CrossRef
  • A Modified Duodenal Neuroendocrine Tumor Staging Schema Better Defines the Risk of Lymph Node Metastasis and Disease-free Survival
    Swapnil D. Kachare, Kendall R. Liner, Nasreen A. Vohra, Emmanuel E. Zervos, Timothy L. Fitzgerald
    The American Surgeon™.2014; 80(8): 821.     CrossRef
  • A Case of Small Cell Neuroendocrine Tumor Occurring at Hilar Bile Duct
    Bum Chul Kim, Tae Jun Song, Hyuk Lee, Mee Joo, Won Ki Bae, Nam-Hoon Kim, Kyung-Ah Kim, June Sung Lee
    The Korean Journal of Gastroenterology.2013; 62(5): 301.     CrossRef
  • Neuroendocrine Tumors
    Young Suk Park
    Korean Journal of Medicine.2013; 85(4): 354.     CrossRef
  • Role of radiotherapy for pancreatobiliary neuroendocrine tumors
    Jeongshim Lee, Jinhyun Choi, Chihwan Choi, Jinsil Seong
    Radiation Oncology Journal.2013; 31(3): 125.     CrossRef
  • Proposal for a Standardized Pathology Report of Gastroenteropancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
    Mee-Yon Cho, Jin Hee Sohn, So Young Jin, Hyunki Kim, Eun Sun Jung, Mi-Jung Kim, Kyoung-Mee Kim, Woo Ho Kim, Joon Mee Kim, Yun Kyung Kang, Joon Hyuk Choi, Dae Young Kang, Youn Wha Kim, Eun Hee Choi
    Korean Journal of Pathology.2013; 47(3): 227.     CrossRef
  • Multiple Neuroendocrine Tumor of the Distal Ileum
    Seung Min Lee, Jong Hoon Lee
    The Korean Journal of Gastroenterology.2013; 61(2): 110.     CrossRef
  • The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study
    Hui-Jen Tsai, Chun-Chieh Wu, Chia-Rung Tsai, Sheng-Fung Lin, Li-Tzong Chen, Jeffrey S. Chang, Olga Y. Gorlova
    PLoS ONE.2013; 8(4): e62487.     CrossRef
  • Which endoscopic treatment is the best for small rectal carcinoid tumors?
    Hyun Ho Choi
    World Journal of Gastrointestinal Endoscopy.2013; 5(10): 487.     CrossRef
  • Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors
    SHUZHENG LIU, YUXI CHANG, JIE MA, XU LI, XIAOHONG LI, JINHU FAN, RONG HUANG, GUANGCAI DUAN, XIBIN SUN
    Oncology Letters.2013; 6(6): 1641.     CrossRef
  • Epidemiology of gastroenteropancreatic neuroendocrine tumours
    M. Fraenkel, M.K. Kim, A. Faggiano, G.D. Valk
    Best Practice & Research Clinical Gastroenterology.2012; 26(6): 691.     CrossRef
  • 25,593 View
  • 290 Download
  • 157 Crossref
Close layer
Case Report
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases
Ji Seon Oh, Jae-Lyun Lee, Mi-Jung Kim, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
Cancer Res Treat. 2006;38(3):178-183.   Published online June 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.3.178
AbstractAbstract PDFPubReaderePub

Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the c-kit gene in two patients, and wild-type c-kit and PDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST.

Citations

Citations to this article as recorded by  
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
    Ki Choon Sim, Beom Jin Park, Na Yeon Han, Deuk Jae Sung, Min Ju Kim, Sung Bum Cho, Hyun Kwon Ha, Hyoung Rae Kim
    Journal of the Korean Society of Radiology.2014; 71(5): 239.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
    Cancer Research and Treatment.2012; 44(2): 85.     CrossRef
  • Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
    Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee
    Journal of the Korean Society of Coloproctology.2011; 27(3): 147.     CrossRef
  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Hye Jin Kang, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
    Journal of Korean Medical Science.2010; 25(11): 1543.     CrossRef
  • Clinical Practice Guideline for Adequate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang
    Journal of the Korean Medical Association.2007; 50(9): 830.     CrossRef
  • 11,236 View
  • 86 Download
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP